Elebsiran
Elebsiran (VIR-2218) is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran can be used for the study of chronic HBV/HDV infections[1][2][3].
Product Specifications
CAS Number
2648009-64-5
Product Name Alternative
VIR-2218
UNSPSC
12352208
Target
HBV; Small Interfering RNA (siRNA)
Type
Oligonucleotides
Related Pathways
Anti-infection; Epigenetics
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/elebsiran-1.html
Solubility
10 mM in H2O
Smiles
[Elebsiran]
Molecular Formula
C485H658N158F9O294P39S6
Molecular Weight
14976.67
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Oligonucleotides
Clinical Information
Phase 3
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
FAM104B Polyclonal Antibody, APC-Cy7 Conjugated
SUPT20HL2 (NM_001136233) Human Recombinant Protein